Lymphangioleiomyomatosis: What do we know and what are we looking for?

European Respiratory Review

Volumn 20, Issue 119, 2011, Pages 34-44

  Harari, S ^a   Torre, O ^a   Moss, J ^b  

^a San Giuseppe Hospital   (Italy)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

LAM cells; Lymphangioleiomyomatosis; Tuberous sclerosis complex

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; DOXYCYCLINE; EVEROLIMUS; GONADORELIN DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OCTREOTIDE; PROGESTERONE; RAPAMYCIN; TUBERIN;

ANGIOMYOLIPOMA; APHTHOUS ULCER; CHYLOTHORAX; CLINICAL FEATURE; COMPLEX FORMATION; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; GENE MUTATION; GENETIC ASSOCIATION; HISTIOCYTOSIS X; HORMONAL THERAPY; HUMAN; IMAGE ANALYSIS; KIDNEY AMYLOIDOSIS; KIDNEY SURGERY; LOW FAT DIET; LUNG LESION; LUNG TUMOR; LYMPHANGIOLEIOMYOMATOSIS; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; NONHUMAN; PLEURA EFFUSION; PLEURODESIS; PNEUMOTHORAX; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY CAPILLARY HEMANGIOMATOSIS; PULMONARY REHABILITATION; REVIEW; THORACOCENTESIS; THORAX RADIOGRAPHY; TUBEROUS SCLEROSIS; UPPER RESPIRATORY TRACT INFECTION;

CELL PROLIFERATION; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LUNG; LYMPHANGIOLEIOMYOMATOSIS; MAGNETIC RESONANCE IMAGING; MYOCYTES, SMOOTH MUSCLE; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SEX FACTORS; SIGNAL TRANSDUCTION; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUBEROUS SCLEROSIS;

EID: 79952409681     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00011010     Document Type: Review

References (138)

1. Kitaichi M, Nishimura K, Itoh H, et al. Pulmonary lymphangio-myomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med 1995; 151: 527-533.
2. Urban T, Lazor R, Lacronique J, et al. Pulmonary lymphangioleio-myomatosis: a study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies ''Orphelines'' Pulmonaires (GERM''O''P). Medicine (Baltimore) 1999; 78: 321-337.
3. Chu SC, Horiba K, Usuki J, et al. Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest 1999; 115: 1041-1052.
4. Johnson SR, Tattersfield AE. Clinical experience of lymphangio-leiomyomatosis in the UK. Thorax 2000; 55: 1052-1057.
5. Ryu JH, Moss J, Beck GJ, et al. The NHLBI Lymphangio-leiomyomatosis Registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 2006; 173: 105-111.
6. Costello LC, Hartman TE, Ryu JH. High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin Proc 2000; 75: 591-594.
7. Franz DN, Brody A, Meyer C, et al. Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleio-myomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med 2001; 164: 661-668.
8. Moss J, Avila NA, Barnes PM, et al. Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am J Respir Crit Care Med 2001; 164: 669-671.
9. Sparagana SP, Roach ES. Tuberous sclerosis complex. Curr Opin Neurol 2000; 13: 115-119.
10. Juvet SC, McCormack FX, Kwiatkowski DJ, et al. Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans. Am J Respir Cell Mol Biol 2006; 38: 398-408.
11. Taveira-Da Silva AM, Moss J. Lymphangioleiomyomatosis. Cancer Control 2006; 13: 276-285.
12. Zhe X, Schuger L. Combined smooth muscle and melanocytic differentiation in lymphangioleiomyomatosis. J Histochem Cytochem 2004; 52: 1537-1542.
13. Matsumoto Y, Horiba K, Usuki J, et al. Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 1999; 21: 327-336.
14. Finlay G. The LAM cell: what is it, where does it come from, and why does it grow? Am J Physiol Lung Cell Mol Physiol 2004; 286: L690-L693.
15. Brentani MM, Carvalho CR, Saldiva PH, et al. Steroid receptors in pulmonary lymphangiomyomatosis. Chest 1984; 85: 96-99.
16. Logginidou H, Ao X, Russo I, et al. Frequent estrogen and progesterone receptor immunoreactivity in renal angiomyolipomas from women with pulmonary lymphangioleiomyomatosis. Chest 2000; 117: 25-30.
17. Barberis M, Monti GP, Ziglio G, et al. Oestrogen and progesterone receptors detection in pulmonary lymphangioleiomyoma-tosis. Am J Respir Crit Care Med 1996; 153: 271.
18. Pea M, Bonetti F, Zamboni G, et al. Melanocyte-marker-HMB-45 is regularly expressed in angiomyolipoma of the kidney. Pathology 1991; 23: 185-188.
19. Avila NA, Dwyer AJ, Rabel A, et al. Sporadic lymphangioleio-myomatosis and tuberous sclerosis complex with lymphangio-leiomyomatosis: comparison of CT features. Radiology 2007; 242: 277-285.
20. Bissler JJ, Kingswood JC. Renal angiomyolipomata. Kidney Int 2004; 66: 924-934.
21. Kwiatkowski DJ. Tuberous sclerosis: from tubers to mTOR. Ann Hum Genet 2003; 67: 87-96.
22. Crooks DM, Pacheco-Rodriguez G, DeCastro RM, et al. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2004; 101: 17462-17467.
23. Karbowniczek M, Astrinidis A, Balsara BR, et al. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 2003; 167: 976-982.
24. Yu J, Astrinidis A, Henske EP. Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangio-myomatosis. Am J Respir Crit Care Med 2001; 164: 1537-1540.
25. Sato T, Seyama K, Fujii H, et al. Mutational analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphan-gileiomyomatosis. J Hum Genet 2002; 47: 20-28.
26. Smolarek TA, Wessner LL, McCormack FX, et al. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 1998; 62: 810-815.
27. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2000; 97: 6085-90.
28. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820-823.
29. van Slegtenhorst M, de Hoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997; 277: 805-808.
30. The European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993; 75: 1305-1315.
31. Rosner M, Freilinger A, Hengstschlager M. Proteins interacting with the tuberous sclerosis gene products. Amino Acids 2004; 27: 119-128.
32. Lamb RF, Roy C, Diefenbach TJ, et al. The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat Cell Biol 2000; 2: 281-287.
33. Haddad LA, Smith N, Bowser M, et al. The TSC1 tumor suppressor hamartin interacts with neurofilament-L and possibly functions as a novel integrator of the neuronal cytoskeleton. J Biol Chem 2002; 277: 44180-44186.
34. van Slegtenhorst M, Nellist M, Nagelkerken B, et al. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum Mol Genet 1998; 7: 1053-1057.
35. Maheshwar MM, Sandford R, Nellist M, et al. Comparative analysis and genomic structure of the tuberous sclerosis 2 (TSC2) gene in human and pufferfish. Hum Mol Genet 1996; 5: 131-137.
36. Dan HC, Sun M, Yang L, et al. Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem 2002; 277: 35364-35370.
37. Inoki K, Li Y, Zhu T, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002; 4: 648-657.
38. Ma L, Chen Z, Erdjument-Bromage H, et al. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005; 121: 179-193.
39. Li Y, Inoki K, Vacratsis P, et al. The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14-3-3. J Biol Chem 2003; 278: 13663-13671.
40. Roux PP, Ballif BA, Anjum R, et al. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA 2004; 101: 13489-13494.
41. Soucek T, Pusch O, Wienecke R, et al. Role of the tuberous sclerosis gene-2 product in cell cycle control. J Biol Chem 1997; 272: 29301-29308.
42. Lamb RF, Roy C, Diefenbach TJ, et al. The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat Cell Biol 2000; 2: 281-287.
43. Johnson MW, Emelin JK, Park SH, et al. Co-localization of TSC1 and TSC2 gene products in tubers of patients with tuberous sclerosis. Brain Pathol 1999; 9: 45-54.
44. Fukuda T, Kobayashi T, Momose S, et al. Distribution of Tsc1 protein detected by immunohistochemistry in various normal rat tissues and the renal carcinomas of Eker rat: detection of limited colocalization with Tsc1 and Tsc2 gene products in vivo. Lab Invest 2000; 80: 1347-1359.
45. Johnson MW, Kerfoot C, Bushnell T, et al. Hamartin and tuberin expression in human tissues. Mod Pathol 2001; 14: 202-210.
46. Catania MG, Johnson MW, Liau LM, et al. Hamartin expression and interaction with tuberin in tumor cell lines and primary cultures. J Neurosci Res 2001; 63: 276-283.
47. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000; 103: 253-262.
48. Barbet NC, Schneider U, Helliwell SB, et al. TOR controls translation initiation and early G1 progression in yeast. Mol Biol Cell 1996; 7: 25-42.
49. Garami A, Zwartkruis FJ, Nobukuni T, et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 2003; 11: 1457-1466.
50. Inoki K, Li Y, Xu T, et al. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003; 17: 1829-1834.
51. Saucedo LJ, Gao X, Chiarelli DA, et al. Rheb promotes cell growth as a component of the insulin/TOR signaling network. Nat Cell Biol 2003; 5: 566-571.
52. Zhang Y, Gao X, Saucedo LJ, et al. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 2003; 5: 578-581.
53. Li Y, Inoki K, Guan KL. Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity. Mol Cell Biol 2004; 24: 7965-7975.
54. Nellist M, Sancak O, Goedbloed MA, et al. Distinct effects of single amino-acid changes to tuberin on the function of the tuberin-hamartin complex. Eur J Hum Genet 2005; 13: 59-68.
55. Dan HC, Sun M, Yang L, et al. Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem 2002; 277: 35364-35370.
56. Inoki K, Li Y, Zhu T, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002; 4: 648-657.
57. Ma L, Chen Z, Erdjument-Bromage H, et al. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005; 121: 179-193.
58. Li Y, Inoki K, Vacratsis P, et al. The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14-3-3. J Biol Chem 2003; 278: 13663-13671.
59. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003; 115: 577-590.
60. Finlay GA, York B, Karas RH, et al. Estrogen-induced smooth muscle cell growth is regulated by tuberin and associated with altered activation of platelet-derived growth factor receptor-beta and ERK-1/2. J Biol Chem 2004; 279: 23114-23122.
61. Simoncini T, Hafezi-Moghadam A, Brazil DP, et al. Interaction of oestrogen receptor with the regulatory subunit of phophas-tidylinositol-3-OH kinase. Nature 2000; 407: 538-541.
62. Flores-Delgado G, Anderson KD, Warburton D. Nongenomic estrogen action regulates tyrosine phosphatase activity and tuberin stability. Mol Cell Endocrinol 2003; 199: 143-151.
63. Yu J, Astrinidis A, Howard S, et al. Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. Am J Physiol Lung Cell Mol Physiol 2004; 286: L694-L700.
64. York B, Lou D, Panettieri RA Jr, et al. Cross-talk between tuberin, calmodulin, and estrogen signaling pathways. FASEB J 2005; 19: 1202-1204.
65. Yu JJ, Robb VA, Morrison TA, et al. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci USA 2009 Feb 24, 106: 2635-2640.
66. Crawford HC, Matrisian LM. Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invasion Metastasis 1994; 14: 234-245.
67. Matsui K, Takeda K, Yu ZX, et al. Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy: an immunohistochemical study. Am J Respir Crit Care Med 2000; 161: 1002-1009.
68. Matsui K, Takeda K, Yu ZX, et al. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphan-gioleiomyomatosis. Arch Pathol Lab Med 2000; 124: 267-275.
69. Hayashi T, Fleming MV, Stetler-Stevenson WG, et al. Immuno-histochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleio-myomatosis (LAM). Hum Pathol 1997; 28: 1071-1078.
70. Chilosi M, Pea M, Martignoni G, et al. Cathepsin-K expression in pulmonary lymphangioleiomyomatosis. Mod Pathol 2009; 22: 161-166.
71. Bromme D, Okamoto K, Wang BB, et al. Humancathepsin O2, a matrix protein-degrading cysteine protease expressed in osteo-clasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme. J Biol Chem 1996; 271: 2126-2132.
72. Merrilees MJ, Hankin EJ, Black JL, et al. Matrix proteoglycans and remodelling of interstitial lung tissue in lymphangioleio-myomatosis. J Pathol 2004; 203: 653-660.
73. Kumasaka T, Seyama K, Mitani K, et al. Lymphangiogenesis in lymphangioleiomyomatosis: its implication in the progression of lymphangioleiomyomatosis. Am J Surg Pathol 2004; 28: 1007-1016.
74. Kumasaka T, Seyama K, Mitani K, et al. Lymphangiogenesis mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am J Surg Pathol 2005; 29: 1356-1366.
75. Travis WD, Usuki J, Horiba K, et al. Histopathologic studies on lymphangioleiomyomatosis. In: Moss J, ed. LAM and other Diseases Characterized by Smooth Muscle Proliferation. New York, Marcel Dekker, Inc., 1999; pp. 171-217.
76. Juvet SC, McCormack FX, Kwiatkowski DJ, et al. Molecular pathogenesis of lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 2007; 36: 398-408.
77. Taveira-Dasilva AM, Stylianou MP, Hedin CJ, et al. Bone mineral density in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2005; 171: 61-67.
78. Taylor JR, Ryu J, Colby TV, et al. Lymphangioleiomyomatosis. Clinical course in 32 patients. N Engl J Med 1990; 323: 1254-1260.
79. Ryu JH, Doerr CH, Fisher SD, et al. Chylothorax in lymphangio-leiomyomatosis. Chest 2003; 123: 623-627.
80. Bissler JJ, Kingswood JC. Renal angiomyolipomata. Kidney Int 2004; 66: 924-934.
81. L'Hostis H, Deminiere C, Ferriere JM, et al. Renal angiomyoli-poma: a clinicopathologic, immunohistochemical, and follow-up study of 46 cases. Am J Surg Pathol 1999; 23: 1011-1020.
82. Bernstein SM, Newell JD Jr, Adamczyk D, et al. How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis? Am J Respir Crit Care Med 1995; 152: 2138-2143.
83. Maziak DE, Kesten S, Rappaport DC, et al. Extrathoracic angio-myolipomas in lymphangioleiomyomatosis. Eur Respir J 1996; 9: 402-405.
84. Avila NA, Kelly JA, Chu SC, et al. Lymphangioleiomyomatosis: abdominopelvic CT and US findings. Radiology 2000; 216: 147-153.
85. Matsui K, Tatsuguchi A, Valencia J, et al. Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathologic features in 22 cases. Hum Pathol 2000; 31: 1242-1248.
86. Avila NA, Bechtle J, Dwyer AJ, et al. Lymphangioleiomyomatosis: CT of diurnal variation of lymphangioleiomyomas. Radiology 2001; 221: 415-421.
87. Moss J, DeCastro R, Patronas NJ, et al. Meningiomas in lymphangioleiomyomatosis. JAMA 2001; 286: 1879-1881.
88. Roach ES, DiMario FJ, Kandt RS, et al. Tuberous Sclerosis Consensus Conference: recommendations for diagnostic evaluation. National Tuberous Sclerosis Association. J Child Neurol 1999; 14: 401-407.
89. Merchant RN, Pearson MG, Rankin RN, et al. Computerized tomography in the diagnosis of lymphangioleiomyomatosis. Am Rev Respir Dis 1985; 131: 295-297.
90. Avila NA, Chen CC, Chu SC, et al. Pulmonary lymphangioleio-myomatosis: correlation of ventilation-perfusion scintigraphy, chest radiography, and CT with pulmonary function tests. Radiology 2000; 214: 441-446.
91. Avila NA, Kelly JA, Dwyer AJ, et al. Lymphangioleiomyomatosis: correlation of qualitative and quantitative thin-section CT with pulmonary function tests and assessment of dependence on pleurodesis. Radiology 2002; 223: 189-197.
92. Helenon O, Merran S, Paraf F, et al. Unusual fat-containing tumors of the kidney: a diagnostic dilemma. Radiographics 1997; 17: 129-144.
93. Johnson SR, Cordier JF, Lazor R, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 2010; 35: 14-26.
94. Koyama M, Johkoh T, Honda O, et al. Chronic cystic lung disease: diagnostic accuracy of high-resolution CT in 92 patients. AJR Am J Roentgenol 2003; 180: 827-835.
95. Harari S, Paciocco G. An integrated clinical approach to diffuse cystic lung diseases. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22: Suppl. 1, S31-S39.
96. Paciocco G, Uslenghi E, Bianchi A, et al. Diffuse cystic lung diseases: correlation between radiologic and functional status. Chest 2004; 125: 135-142.
97. Jeong YJ, Lee KS, Chung MP, et al. Amyloidosis and lympho-proliferative disease in Sjogren syndrome: thin-section computed tomography findings and histopathologic comparisons. J Comput Assist Tomogr 2004; 28: 776-781.
98. Johkoh T, Muller NL, Pickford HA, et al. Lymphocytic interstitial pneumonia: thin-section CT findings in 22 patients. Radiology 1999; 212: 567-572.
99. Silva CI, Churg A, Muller NL. Hypersensitivity pneumonitis: spectrum of high-resolution CT and pathologic findings. AJR Am J Roentgenol 2007; 188: 334-344.
100. Colombat M, Stern M, Groussard O, et al. Pulmonary cystic disorder related to light chain deposition disease. Am J Respir Crit Care Med 2006; 173: 777-780.
101. Aubry MC, Myers JL, Colby TV, et al. Endometrial stromal sarcoma metastatic to the lung: a detailed analysis of 16 patients. Am J Surg Pathol 2002; 26: 440-449.
102. Ayo DS, Aughenbaugh GL, Yi ES, et al. Cystic lung disease in Birt-Hogg-Dube syndrome. Chest 2007; 132: 679-684.
103. Young LR, Inoue J, McCormack FX. Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med 2008; 358: 199-200.
104. Young LR, Vandyke R, Gulleman PM, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lym-phangioleiomyomatosis from other diseases. Chest 2010; 138: 674-681.
105. Glasgow CG, Avila NA, Lin JP, et al. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyoma-tosis reflect lymphatic involvement. Chest 2009; 135: 1293-1300.
106. Faul JL, Berry GJ, Colby TV, et al. Thoracic lymphangiomas,lym-phangiectasis, lymphangiomatosis, and lymphatic dysplasia syndrome. Am J Respir Crit Care Med 2000; 161: 1037-1046.
107. Almoosa KF, Ryu JH, Mendez J, et al. Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications. Chest 2006; 129: 1274-1281.
108. Almoosa KF, McCormack FX, Sahn SA. Pleural disease in lymphangioleiomyomatosis. Clin Chest Med 2006; 27: 355-368.
109. Kalomenidis I. Octreotide and chylothorax. Curr Opin Pulm Med 2006; 12: 264-267.
110. Demos NJ, Kozel J, Scerbo JE. Somatostatin in the treatment of chylothorax. Chest 2001; 119: 964-966.
111. Hsu TH, O'Hara J, Mehta A, et al. Nephron-sparing nephrectomy for giant renal angiomyolipoma associated with lymphangio-leiomyomatosis. Urology 2002; 59: 138.
112. Taveira-DaSilva AM, Hedin C, Stylianou MP, et al. Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2001; 164: 1072-1076.
113. Taveira-DaSilva AM, Steagall WK, Rabel A, et al. Reversible airflow obstruction in lymphangioleiomyomatosis. Chest 2009; 136: 1596-1603.
114. Brunelli A, Catalini G, Fianchini A. Pregnancy exacerbating unsuspected mediastinal lymphangioleiomyomatosis and chy-lothorax. Int J Gynaecol Obstet 1996; 52: 289-290.
115. Yano S. Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous oestrogen used for infertility treatment. Thorax 2002; 57: 1085-1086.
116. Eliasson AH, Phillips YY, Tenholder MF. Treatment of lymphangioleiomyomatosis: a meta-analysis. Chest 1989; 96: 1352-1355.
117. Rossi GA, Balbi B, Oddera S, et al. Response to treatment with an analog of luteinizing-hormone-releasing hormone in a patient with pulmonary lymphangioleiomyomatosis. Am Rev Respir Dis 1991; 143: 174-176.
118. Medeiros P Jr, Kairalla RA, Pereira CAC, et al. GnRH analogs X progesterone-lung function evolution in two treatment cohort groups in lymphangioleiomyomatosis (LAM). Am J Respir Crit Care Med 2003; 167: A953.
119. de la Fuente J, Parámo C, Román F, et al. Lymphangioleiomyomatosis: unsuccessful treatment with luteinizing-hormone-releasing hormone analogues. Eur J Med 1993; 2: 377-378.
120. Zahner J, Borchard F, Fischer H, et al. Successful therapy of a post-partum lymphangioleiomyomatosis. Case report and literature review. Schweiz Med Wochenschr 1994; 124: 1626-1632.
121. Harari S, Cassandro R, Chiodini I, et al. Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis. Chest 2008; 133: 448-454.
122. McCarty KS, Mossler JA, McLelland R, et al. Pulmonary lymphangiomyomatosis responsive to progesterone. N Engl J Med 1980; 303: 1461-1465.
123. Sieker HO, McCarty KS Jr. Lymphangiomyomatosis: a respiratory illness with an endocrinologic therapy. Trans Am Clin Climatol Assoc 1987; 99: 57-67.
124. Johnson SR, Tattersfield AE. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am J Respir Crit Care Med 1999; 160: 628-633.
125. Taveira-Dasilva AM, Stylianou MP, Hedin CJ, et al. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 2004; 126: 1867-1874.
126. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangio-leiomyomotosis. N Engl J Med 2008; 358: 140-151.
127. Davies DM, Johnson SR, Tattersfield AE, et al. Sirolimus therapy in tuberous sclerosis or sporadic Lymphangioleiomyomatosis. N Engl J Med 2008; 358: 200-203.
128. Schneider BS, Maimon J, Golub LM, et al. Tetracyclines inhibit intracellular muscle proteolysis in vitro. Biochem Biophys Res Commun 1992; 188: 767-772.
129. Ginns LC, Roberts DH, Mark EJ, et al. Pulmonary capillary hemangiomatosis with atypical endotheliomatosis: successful antiangiogenic therapy with doxycycline. Chest 2003; 124: 2017-2022.
130. Moses MA, Harper J, Folkman J. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med 2006; 354: 2621-2622.
131. El-Hashemite N, Walker V, Kwiatkowski DJ. Estrogen enhances whereas tamoxifen retards development of Tsc mouse liver hemangioma: a tumor related to renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. Cancer Res 2005; 65: 2474-2481.
132. Mendel DB, Laird AD, Smolich BD, et al. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des 2000; 15: 29-41.
133. Mross K, Drevs J, Muller M, et al. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer 2005; 41: 1291-1299.
134. Jones-Bolin S, Zhao H, Hunter K, et al. The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice. Mol Cancer Ther 2006; 5: 1744-1753.
135. Fritz G, Kaina B. Rho GTPases: promising cellular targets for novel anticancer drugs. Curr Cancer Drug Targets 2006; 6: 1-14.
136. Gau CL, Kato-Stankiewicz J, Jiang C, et al. Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways. Mol Cancer Ther 2005; 4: 918-926.
137. El-Chemaly S, Taveira-Da Silva A, Stylianou MP, et al. Statins in lymphangioleiomyomatosis: a word of caution. Eur Respir J 2009; 34: 513-520.
138. Nurok M, Eslick I, Carvalho CR, et al. The international LAM registry: a component of an innovative web-based clinician, researcher, and patient-driven rare disease research platform. Limphat Res Biol 2010; 8: 81-87.